| Syk tyrosine kinase is linked to cell motility and progression in squamous cell carcinomas of the head and neck S Luangdilok, C Box, L Patterson, W Court, K Harrington, L Pitkin, ... Cancer research 67 (16), 7907-7916, 2007 | 97 | 2007 |
| Association between pathological complete response and outcome following neoadjuvant chemotherapy in locally advanced breast cancer patients S Luangdilok, N Samarnthai, K Korphaisarn Journal of breast cancer 17 (4), 376, 2014 | 63 | 2014 |
| MAPK and PI3K signalling differentially regulate angiogenic and lymphangiogenic cytokine secretion in squamous cell carcinoma of the head and neck S Luangdilok, C Box, K Harrington, P Rhŷs-Evans, S Eccles European journal of cancer 47 (4), 520-529, 2011 | 61 | 2011 |
| Expression of CC chemokine receptor 7 in tonsillar cancer predicts cervical nodal metastasis, systemic relapse and survival L Pitkin, S Luangdilok, C Corbishley, POG Wilson, P Dalton, D Bray, ... British journal of cancer 97 (5), 670-677, 2007 | 35 | 2007 |
| Court W, Harrington K, Pitkin L, Rhys-Evans P, O-charoenrat P, Eccles S. Syk tyrosine kinase is linked to cell motility and progression in squamous cell carcinomas of the head … S Luangdilok, C Box, L Patterson Cancer Res 67 (16), 7907-7916, 2007 | 25 | 2007 |
| Cyclin D1 expression as a potential prognostic factor in advanced KRAS-mutant non-small cell lung cancer S Luangdilok, P Wanchaijiraboon, P Chantranuwatana, C Teerapakpinyo, ... Translational Lung Cancer Research 8 (6), 959, 2019 | 15 | 2019 |
| Immunogenicity of ChAdOx1-nCoV-19 vaccine in solid malignancy patients by treatment regimen versus healthy controls: a prospective, multicenter observational study N Teeyapun, S Luangdilok, N Pakvisal, P Sainamthip, S Mingmalairak, ... EClinicalMedicine 52, 2022 | 8 | 2022 |
| Vaccine-Related adverse events following AZD1222 (ChAdOx1-nCoV-19) Covid-19 vaccine in solid malignancy patients receiving cancer treatment, as compared to age-matched healthy … N Pakvisal, P Sainamthip, N Teeyapun, S Luangdilok, N Wanlapakorn, ... Human Vaccines & Immunotherapeutics 18 (6), 2094149, 2022 | 6 | 2022 |
| Immunogenicity after a third COVID-19 mRNA booster in solid cancer patients who previously received the primary heterologous CoronaVac/ChAdOx1 vaccine S Luangdilok, P Wanchaijiraboon, N Pakvisal, T Susiriwatananont, ... Vaccines 10 (10), 1613, 2022 | 6 | 2022 |
| Durability of Immune Response to ChAdOx1-nCoV-19 Vaccine in Solid Cancer Patients Undergoing Anticancer Treatment P Wanchaijiraboon, N Teeyapun, N Pakvisal, P Sainamthip, ... Vaccines 10 (10), 1662, 2022 | 3 | 2022 |
| Immunogenicity and Omicron Neutralization Following a Third COVID-19 Vaccination in Solid Cancer Patients Previously Primed with Two Doses of Chadox1 Vaccine: A Prospective … S Luangdilok, P Wanchaijiraboon, N Pakvisal, T Susiriwatananont, ... | 2 | 2022 |
| Safety Following COVID-19 Booster Vaccine with BNT162b2 Compared to mRNA-1273 in Solid Cancer Patients Previously Vaccinated with ChAdOx1 or CoronaVac P Wanchaijiraboon, P Sainamthip, N Teeyapun, S Luangdilok, ... Vaccines 11 (2), 356, 2023 | 1 | 2023 |
| HSR22-172: Immunogenicity of ChAdOx1-nCoV-19 Vaccination for Solid Cancer Patients, Prospective Observational Multicenter Study-Preliminary Report N Teeyapun, PP Wanchaijiraboon, N Pakvisal, P Sainamthip, ... Journal of the National Comprehensive Cancer Network 20 (3.5), HSR22-172 …, 2022 | 1 | 2022 |
| Efficacy and safety of additional olanzapine to ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting: A randomized, double-blind, placebo … V Vimolchalao, S Sakdejayont, P Wongchanapai, S Sukprakun, ... Journal of Clinical Oncology 36 (15_suppl), 10019-10019, 2018 | 1 | 2018 |
| Tissue and Plasma-Based Highly Sensitive Blocker Displacement Amplicon Nanopore Sequencing for EGFR Mutations in Lung Cancer P Akkhasutthikun, P Kaewsapsak, P Nimsamer, P Klomkliew, ... Cancer Research and Treatment: Official Journal of Korean Cancer Association …, 2024 | | 2024 |
| MO72-6 Health-related quality of life in different states of Thai patients with breast cancer–preliminary report S Luangdilok, C Chanatittarat, N Parinyanitikul, S Lochid-Amnuay Annals of Oncology 34, S1441-S1442, 2023 | | 2023 |
| OP12 Durability and immunogenicity after two doses of ChAdOx1 nCov-19 among the type of cancer treatment in oncologic patients: A prospective, multicenter observational study P Wanchaijiraboon, N Teeyapun, S Luangdilok, N Wanlapakorn, ... ESMO Open 7 (6), 2022 | | 2022 |
| Vaccine-related adverse events following ChAdOx1-nCoV-19 vaccine in actively treated patients with solid malignancy, as compared to age-matched healthy controls. N Pakvisal, P Sainamthip, N Teeyapun, S Luangdilok, P Wanchaijiraboon, ... Journal of Clinical Oncology 40 (16_suppl), e13517-e13517, 2022 | | 2022 |
| MCM4 as a prognostic biomarker of early-stage lung cancer. V Sriuranpong, S Luangdilok, P Chantranuwatana, N Leeladejkul, ... Journal of Clinical Oncology 38 (15_suppl), e21033-e21033, 2020 | | 2020 |
| Characteristics of K-ras mutation lung cancer in an East Asian institute. P Wanchaijiraboon, V Sriuranpong, S Luangdilok, P Chantranuwat Journal of Clinical Oncology 36 (15_suppl), e21206-e21206, 2018 | | 2018 |
